Last reviewed · How we verify
RiTUXimab Injection [Truxima]
Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.
Rituximab Injection (Truxima) is a biosimilar monoclonal antibody targeting CD20-positive B cells, used primarily in the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It has no FDA label or clinical trials listed, indicating limited regulatory approval and research activity.
At a glance
| Generic name | RiTUXimab Injection [Truxima] |
|---|---|
| Sponsor | Laida Cuevas Palomares |
| Drug class | Monoclonal antibody (anti-CD20) |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | FDA-approved |
Mechanism of action
Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers multiple mechanisms of B cell destruction including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This results in rapid depletion of B cells, reducing autoimmune and malignant B cell populations.
Approved indications
- Non-Hodgkin's lymphoma (B-cell)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Common side effects
- Infusion reactions
- Fever
- Chills
- Infections
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RiTUXimab Injection [Truxima] CI brief — competitive landscape report
- RiTUXimab Injection [Truxima] updates RSS · CI watch RSS
- Laida Cuevas Palomares portfolio CI